Geron, FDA reach deal regarding trials of spinal-injury therapy
Geron said it might be able to resume early-stage trials of a stem cell treatment for complete thoracic spinal cord injury by the third quarter of 2010 under an agreement with the FDA. The agency had placed the studies on clinical hold after the treatment caused cysts in some animal subjects.
Reuters | 10/30
This story published in BIO SmartBrief on 11/02/2009
More from SmartBrief:
FDA delays human trials of Geron's embryonic stem cell therapy
Wednesday, August 19, 2009
Geron: Animals injected with spinal injury drug formed cysts
Friday, August 28, 2009
LucCell uses optogenetics to treat brain disorders
Wednesday, September 2, 2009
Get stories like these delivered daily for FREE:
|
BIO SmartBrief
Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more |
|